Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;2(2):59-64.
doi: 10.1177/2042018811398517.

Challenges in β(3)-Adrenoceptor Agonist Drug Development

Jonathan R S Arch

Challenges in β(3)-Adrenoceptor Agonist Drug Development

Jonathan R S Arch. Ther Adv Endocrinol Metab. 2011 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Arch J.R. (2002) β3-Adrenoceptor agonists: Potential, pitfalls and progress. Eur J Pharmacol 440: 99–107 - PubMed
    1. Arch J.R. (2004) Do low-affinity states of β-adrenoceptors have roles in physiology and medicine?. Br J Pharmacol 143: 517–518 - PMC - PubMed
    1. Arch J.R. (2008) The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: Perspectives from β3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 378: 225–240 - PubMed
    1. Arch J.R.S. (1989) The brown adipocyte β-adrenoceptor. Proc Nutr Soc 48: 215–223 - PubMed
    1. Arch J.R.S. (2011) Thermogenesis and related metabolic targets in anti-diabetic therapy, In: Schwanstecher M. (ed.). Handbook of Experimental Pharmacology — Diabetes, Springer: Heidelberg, in press. - PubMed

LinkOut - more resources